Sanofi's new head of specialty care Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 20 February, 2026

AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.

presented by Lessons in Cat­e­go­ry Cre­ation: In Con­ver­sa­tion with Bob­by Aza­mi­an, CEO Tar­sus Phar­ma­ceu­ti­cals

news Grail's cancer test shows promise, but misses primary goal in UK study Novartis to divest India unit to private equity-led consortium for $159M  Peer Review Sanofi appoints specialty care head; Biogen chair to retire in June

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group United States Vice President, Drug Metabolism & Pharmacokinetics (DMPK) C4 Therapeutics Watertown, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Innovation in biopharmaceuticals: A conversation with Fujifilm leaders sponsored by Fujifilm From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

ENDPOINTS PHARMA AbbVie, PhRMA can proceed with 340B case in Hawaii Teva beats Corcept in appeals fight over generic Cushing's syndrome drug Hims is buying an Australian telehealth company for $240M upfront

in case you missed it 1. Makary, Prasad set one pivotal trial policy via NEJM article 2. Obesity biotech Verdiva gears up for a big year of data — and maybe deals too 3. News Briefing Biogen stops part of an MS trial; Merck reports more Enflonsia data 4. Led by former Trump official, Altesa raises $75M to advance respiratory med 5. J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug 6. J&J Explores $20 Billion-Plus Sale of Orthopedics Unit 7. Japan panel approves world's first iPS cell-based therapies